Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

This study is testing a combination treatment — camrelizumab (an immunotherapy drug), apatinib (a targeted drug that blocks blood vessel growth), and TACE (a procedure that delivers chemotherapy directly to the liver) — in people with liver cancer before and after surgery. **You may be eligible if...** - You are 18 or older with liver cancer (hepatocellular carcinoma) confirmed by biopsy, lab, or imaging - Your liver cancer is at an intermediate or advanced local stage (specific Chinese staging criteria apply) - Your liver function is reasonably preserved (Child-Pugh grade A) - Your general health score is 0 or 1 (meaning you are active and able to care for yourself) **You may NOT be eligible if...** - You have a mixed or rare type of liver cancer (such as cholangiocarcinoma or fibrolamellar carcinoma) - You have another active cancer - You have active autoimmune disease or a history that may flare - You have a serious current infection or fever - You have HIV or another immune deficiency - You are allergic to immunotherapy or anti-angiogenesis drugs Talk to your doctor to see if this trial is right for you.